Cerus Corp (CERS):企業の製品パイプライン分析

◆英語タイトル:Cerus Corp (CERS) - Product Pipeline Analysis, 2020 Update
◆商品コード:GDME26394PD
◆発行会社(調査会社):GlobalData
◆発行日:2021年1月
◆ページ数:40
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Medical Devices
◆販売価格オプション(消費税別)
Site License(同一事業所内共有可)USD1,500 ⇒換算¥165,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD2,250 ⇒換算¥247,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Cerus Corp (Cerus) is a biomedical products company that focuses in the field of blood transfusion safety. It develops and commercializes Intercept Blood System, which reduces the risk of transfusion-transmitted infections by inactivating a wide range of pathogens including viruses, bacteria and parasites present in donated blood. The product is for use with three blood components,: platelets, plasma and red blood cells. Cerus’ Intercept blood system is marketed and sold by its direct sales force and distributors in several countries worldwide including the US, Belgium, Kuwait, France, Spain, Portugal, Switzerland, Commonwealth of Independent States (CIS) countries and other countries. Cerus is headquartered in Concord, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

- The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
- The report analyzes all pipeline products in development for the company Cerus Corp
- The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
- The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
- The report provides detailed description of products in development, technical specification and functions
- The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
- Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
- To formulate effective Research & Development strategies
- Develop market-entry and market expansion strategies
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
- Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Cerus Corp Company Overview
Cerus Corp Company Snapshot
Cerus Corp Pipeline Products and Ongoing Clinical Trials Overview
Cerus Corp – Pipeline Analysis Overview
Business Description
Cerus Corp – Key Facts
Cerus Corp – Major Products and Services
Cerus Corp Pipeline Products by Development Stage
Cerus Corp Ongoing Clinical Trials by Trial Status
Cerus Corp Pipeline Products Overview
INTERCEPT Blood System – Platelets
INTERCEPT Blood System – Platelets Product Overview
INTERCEPT Blood System – Platelets Clinical Trial
INTERCEPT Blood System – Red Blood Cells
INTERCEPT Blood System – Red Blood Cells Product Overview
INTERCEPT Blood System – Red Blood Cells Clinical Trial
INTERCEPT Blood System – Whole Blood
INTERCEPT Blood System – Whole Blood Product Overview
INTERCEPT Pathogen Reduced Cryoprecipitate – Poor Plasma
INTERCEPT Pathogen Reduced Cryoprecipitate – Poor Plasma Product Overview
Next Generation INTERCEPT Blood System
Next Generation INTERCEPT Blood System Product Overview
NTERCEPT Pathogen-Reduced Cryoprecipitated Fibrinogen Complex
NTERCEPT Pathogen-Reduced Cryoprecipitated Fibrinogen Complex Product Overview
Cerus Corp – Key Competitors
Cerus Corp – Key Employees
Cerus Corp – Key Employee Biographies
Cerus Corp – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Cerus Corp, Recent Developments
Apr 02, 2020: Cerus Corporation announces the inclusion of pathogen reduction technology in the ISBT working party recommendations for the preparation of COVID-19 convalescent plasma
Feb 18, 2020: U.S. Department of Defense awards funding for study to evaluate the use of INTERCEPT Plasma in traumatic burn resuscitation
Jan 23, 2020: Coronavirus inactivation reported in recent INTERCEPT Blood System publication in transfusion medicine
Jan 21, 2020: French Hemovigilance report highlights safety and effectiveness of INTERCEPT Platelets during first full year of 100% production and routine use
Oct 30, 2019: Cerus announces third quarter 2019 results
Oct 18, 2019: Cerus announces schedule of presentations at the 2019 AABB Annual Meeting
Sep 30, 2019: Cerus Corporation Applauds the Publication of the Final Guidance Document on Bacterial Safety Standards for Platelet Collection and Transfusion
Aug 01, 2019: Cerus announces record second quarter 2019 results
Jun 24, 2019: Cerus announces presentations highlighting INTERCEPT Blood System at the 29th Regional Congress of the ISBT
Jun 03, 2019: Cerus announces new corporate brand and global headquarters
Appendix
Methodology
About GlobalData
Contact Us
Disclaimer

List of Tables
Cerus Corp Pipeline Products and Ongoing Clinical Trials Overview
Cerus Corp Pipeline Products by Equipment Type
Cerus Corp Pipeline Products by Indication
Cerus Corp Ongoing Clinical Trials by Trial Status
Cerus Corp, Key Facts
Cerus Corp, Major Products and Services
Cerus Corp Number of Pipeline Products by Development Stage
Cerus Corp Pipeline Products Summary by Development Stage
Cerus Corp Ongoing Clinical Trials by Trial Status
Cerus Corp Ongoing Clinical Trials Summary
INTERCEPT Blood System - Platelets - Product Status
INTERCEPT Blood System - Platelets - Product Description
INTERCEPT Blood System - Platelets - A Randomized, Multi-center, Multi-Stage, Controlled, In Vivo Study to Assess the Recovery and Survival of Radiolabeled Autologous INTERCEPT Apheresis Platelet Components Suspended in 100% Plasma Stored for up to 7 Days
INTERCEPT Blood System - Red Blood Cells - Product Status
INTERCEPT Blood System - Red Blood Cells - Product Description
INTERCEPT Blood System - Red Blood Cells - A Randomized, Double-blinded, Controlled, Parallel Group, Non-inferiority, Phase III Study to Evaluate the Efficacy and Safety of the INTERCEPT Blood System for Red Blood Cells in Patients Undergoing Complex Cardiac Surgery Procedures
INTERCEPT Blood System - Red Blood Cells - Measurement of the Recovery and Lifespan of Red Blood Cells from Pathogen-reduced, Stored Blood Units Using Cellular Biotinylation
INTERCEPT Blood System - Red Blood Cells - Randomized, Double-blind, Controlled, Parallel Group Study with the INTERCEPT Blood System for RBCs in Regions at Potential Risk for Zika Virus Transfusion-transmitted Infections and Treatment Use Open-label Extension Study
INTERCEPT Blood System - Whole Blood - Product Status
INTERCEPT Blood System - Whole Blood - Product Description
INTERCEPT Pathogen Reduced Cryoprecipitate - Poor Plasma - Product Status
INTERCEPT Pathogen Reduced Cryoprecipitate - Poor Plasma - Product Description
Next Generation INTERCEPT Blood System - Product Status
Next Generation INTERCEPT Blood System - Product Description
NTERCEPT Pathogen-Reduced Cryoprecipitated Fibrinogen Complex - Product Status
NTERCEPT Pathogen-Reduced Cryoprecipitated Fibrinogen Complex - Product Description
Cerus Corp, Key Employees
Cerus Corp, Key Employee Biographies
Cerus Corp, Subsidiaries
Glossary

★海外企業調査レポート[Cerus Corp (CERS):企業の製品パイプライン分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bertelsmann SE & Co. KGaA:企業の戦略・SWOT・財務分析
    Bertelsmann SE & Co. KGaA - Strategy, SWOT and Corporate Finance Report Summary Bertelsmann SE & Co. KGaA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Service Corporation International (SCI):企業の財務・戦略的SWOT分析
    Service Corporation International (SCI) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths …
  • Arsenal Holdings PLC (AFC):企業の財務・戦略的SWOT分析
    Arsenal Holdings PLC (AFC) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • General Dynamics United Kingdom Limited:企業の戦略・SWOT・財務情報
    General Dynamics United Kingdom Limited - Strategy, SWOT and Corporate Finance Report Summary General Dynamics United Kingdom Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Meridian Energy Limited:企業の戦略・SWOT・財務情報
    Meridian Energy Limited - Strategy, SWOT and Corporate Finance Report Summary Meridian Energy Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Vascular Biogenics Ltd (VBLT):企業の財務・戦略的SWOT分析
    Summary Vascular Biogenics Ltd (VBL Therapeutics) is a biopharmaceutical company. It discovers, develops and commercializes gene-therapy medicines for the treatment of cancer and inflammatory diseases. The company’s lead product candidate VB-111, a gene-based biologic agent is developed to treat rec …
  • Luitpold Pharmaceuticals Inc-製薬・医療分野:企業M&A・提携分析
    Summary Luitpold Pharmaceuticals Inc (Luitpold), a subsidiary of Daiichi Sankyo Company Ltd is a manufacturer and marketer of drugs and medical devices. The company provides injectable parenteral medications that are used in pharmacy admixtures and nutrient solutions, antidotes, critical care drugs, …
  • Grande Asset Hotels And Property Pcl
    Grande Asset Hotels And Property Pcl - Strategy, SWOT and Corporate Finance Report Summary Grande Asset Hotels And Property Pcl - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • Relief Therapeutics Holding AG (RLF):企業の財務・戦略的SWOT分析
    Summary Relief Therapeutics Holding AG (Relief Therapeutics) is a drug development company that offers clinical development of peptides and proteins of natural or engineered origin. Its pipeline drug candidates include aviptadil for the treatment of sarcoidosis and low dose interleukin-6 to treat pe …
  • Macro Enterprises Inc (MCR):企業の財務・戦略的SWOT分析
    Summary Macro Enterprises Inc (Macro Enterprises) is an oil and gas company that offers pipeline and facility construction and maintenance services. The company provides gathering, processing, transmission, storage and distribution of pipeline systems. It offers fabrication and installation of pipin …
  • Cott Corporation:企業の戦略・SWOT・財務情報
    Cott Corporation - Strategy, SWOT and Corporate Finance Report Summary Cott Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • PTC Therapeutics Inc (PTCT)-製薬・医療分野:企業M&A・提携分析
    Summary PTC Therapeutics Inc (PTC Therapeutics) discovers, develops, and commercializes orally active small molecule therapeutics that target post transcriptional control. The company's pipeline products include an orally administered small-molecule targeted at genetic disorders due to a nonsense mu …
  • Mediobanca – Banca di Credito Finanziario SpA (MB):企業の財務・戦略的SWOT分析
    Mediobanca - Banca di Credito Finanziario SpA (MB) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key …
  • Neuland Laboratories Ltd (NEULANDLAB):製薬・医療:M&Aディール及び事業提携情報
    Summary Neuland Laboratories Ltd (Neuland Lab), a subsidiary of Neuland Health Sciences Pvt Ltd is an API manufacturing service provider that manufactures active pharmaceutical ingredients, advanced intermediates; and offers chemistry related services. The company provides APIs in various therapeuti …
  • Peters Surgical:医療機器:M&Aディール及び事業提携情報
    Summary Peters Surgical (Peters), a subsidiary of Eurazeo SA, is a medical device company that designs, manufactures and distributes surgical products. The company offers products such as catheters, sutures, surgical glue, cardiac ring, single use instrument and accessories for surgical procedures. …
  • Pharmaceutics International Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Pharmaceutics International Inc (PII) is a contract development and manufacturing organization that offers pharmaceutical product development solutions. The organization offers manufacturing of solid, semi-solid, liquid, inhalation, parenteral and aseptic filling drugs. Its services comprise …
  • Barton Malow Co:企業の戦略的SWOT分析
    Barton Malow Co - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • State Atomic Energy Corporation Rosatom:企業の戦略的SWOT分析
    State Atomic Energy Corporation Rosatom - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and m …
  • Boston Children’s Hospital:医療機器:M&Aディール及び事業提携情報
    Summary Boston Children's Hospital (Boston Children’s) is the pediatric medical center that provides a comprehensive range of health care services for children from birth through 21 years of age. Boston Children’s is the primary pediatric teaching affiliate of Harvard Medical School. The organizatio …
  • Metro Inc.:企業の戦略・SWOT・財務情報
    Metro Inc. - Strategy, SWOT and Corporate Finance Report Summary Metro Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actio …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆